Proarrhythmic Effects of Azithromycin
syndrome, where Na + current is downregulated. In the setting of overdose and intravenous administration, 14, 15 azithromycin can cause QRS widening suggesting I Na block, but this has not been reported during oral dosing. Second, excessive prolongation of ventricular repolarization promotes abnormal triggered activity in the form of early afterdepolarizations and ultimately torsades de pointes. 16 QT prolongation occurs with either reduced outward or increased inward currents, and it accounts for the increased risk associated with K + channel-blocking antiarrhythmic drugs, 17, 18 as well as the congenital long-QT syndrome. 19 Reports indicate that the incidence of drug-induced long-QT syndrome with azithromycin is less than that seen with the older macrolides and that torsades de pointes is unusual. Third, patients can develop polymorphic ventricular tachyarrhythmias in the setting of a normal QT interval, 13, 20, 21 exemplified by bidirectional ventricular tachycardia (VT) that can occur with digitalis therapy. Digoxin-mediated inhibition of the Na + -K + ATPase causes intracellular Na + loading, disrupting intracellular Ca ++ homeostasis via reverse mode Na + -Ca ++ exchange, with increased intracellular Ca ++ causing delayed afterdepolarizations and VT. Similarly, spontaneous Ca ++ release from the sarcoplasmic reticulum during catecholaminergic polymorphic VT results in polymorphic VT in the absence of QT prolongation.
A previous case report suggested that azithromycin could cause a distinct, previously undescribed type of drug-induced proarrhythmia, manifested by rapid polymorphic VT in the absence of ECG or structural abnormalities: specifically the QT was normal, with no pause before the tachycardia. 6 We describe a similar case and together, these data imply a novel proarrhythmic mechanism. Accordingly, we examined the electrophysiological effects of azithromycin in vivo and in vitro to investigate the molecular basis for this unusual form of drug-mediated proarrhythmia.
Methods

Reagents
Azithromycin was provided by Pfizer, Inc (Groton, CT) and dissolved in dimethyl sulfoxide to generate a 100 mmol/L stock solution (stored at −20°C). The stock solution was serially diluted in bath solution to the final concentrations before each experiment. The drug was prepared for oral administration as described previously. 22 
Cell Preparations
The effects of azithromycin on the ionic currents under study were investigated using heterologously expressed human channels and cardiomyocytes. For cardiomyocyte studies, the species selected for experimentation was one that would optimize recording conditions for the specific current under study.
Human embryonic kidney (HEK 293) cells that stably expressed either human KCNH2 (hERG) or human SCN5A were kindly provided by Dr Craig January (University of Wisconsin) and Dr Alfred George (Northwestern University), respectively. A Chinese hamster ovary (CHO) cell line stably expressing KCNQ1 and KCNE1 to generate I Ks currents was also provided by Dr George. The construct encoding the human Kir2.1 channel was kindly provided by Dr Antonin Lapoli, with transient transection in HEK cells as reported previously. 23, 24 HEK293, CHO, and HL-1 cells were cultured as described. 23, [25] [26] [27] [28] Isolation of rabbit ventricular myocytes was performed using the method of Bassani 29 with minor modifications. Murine left ventricular myocytes were prepared from 10-to 12-week-old male mice as previously described. 30 The investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication no. 85-23, revised 1996).
Data Acquisition
Mouse ECGs
A DSI (Data Science International, St Paul, MN) telemetry system was used to monitor and collect ECG data from conscious, freely moving laboratory mice. C57BL/6 mice (age 10-12 weeks) were anesthetized using ketamine 100 μg/g and xylazine 10 μg/g injected IP to place a radio transmitter (EA-F20) in the abdominal cavity. The mouse ECG telemetry system contains 2 electrical ECG leads connected to a radio transmitter with subcutaneous electrodes in a lead Ι configuration. On activation of the transmitter by a magnet, the electrical signals were transmitted wirelessly to a nearby receiver (RPC-1) attached to an amplifier (MX2) and computer system for data acquisition (Ponemah v6.10; sampling frequency 2 KHz), storage, and analysis. Animals were allowed to recover for at least 5 days after surgery before experimentation. Each mouse served as its own control with resting ECG recorded for at least 15 to 30 minutes before any intervention. For IP administration, azithromycin 50 mg/kg was injected, followed by 100 mg/kg IP 1 hour later. ECG monitoring continued for at least 1 hour after the second injection. A separate group of mice were treated with oral azithromycin for 3 days, using a dose that was efficacious in treating infections. 31 Baseline ECG was recorded, azithromycin 50 mg/kg was administered by oral gavage, and the ECG was recorded for 2 hours. This was repeated for 2 or 3 additional days.
Action Potentials
Spontaneous action potentials were recorded at 37°C from HL-1 cells as previously described (Data Supplement). 28 Cells chosen for experimentation had a resting membrane potential of at least −55 mV, overshoot exceeding 20 mV, regular rhythmicity, and a stable spontaneous cycle length for at least 5 minutes.
WHAT IS KNOWN
• The commonly used antibiotic azithromycin increases risk of cardiovascular and sudden cardiac death, but the underlying mechanisms are unclear.
• While torsades de pointes is rare, case reports indicate that azithromycin can also cause a novel proarrhythmic syndrome, characterized by polymorphic ventricular tachycardia in the setting of a normal QT interval.
WHAT THE STUDY ADDS
• Acutely, azithromycin causes diffuse depression of the cardiac conduction system and ion channel block, reminiscent of azithromycin overdose in humans.
• Chronically, the drug markedly potentiates cardiac sodium current to promote intracellular sodium loading, a condition associated with intracellular calcium overload and polymorphic ventricular tachycardia.
• These findings provide a unifying mechanistic basis for the novel form of proarrhythmia seen with azithromycin, which likely contributes to the increased risk of sudden cardiac death seen with this antibiotic.
Ionic Currents
All currents were recorded at room temperature (22±1°C) in the whole-cell configuration with an Axopatch-200B amplifier (Molecular Devices, Sunnyvale, CA). Currents were low-pass filtered at 5 kHz and digitized with a DigiData 1320A. Capacitance and 80-95% series resistance were routinely compensated. Leak subtraction was completed using user-specified after-the factleakage correction of pCLAMP. Na + current, rapidly activating (I Kr ) and slowly activating (I Ks ) delayed rectifier K + currents, L-and T-type Ca 2+ currents, and inward rectifier current (I K1 ) were recorded as detailed in the Data Supplement. Pipettes were pulled (Sutter Instrument, Novato, CA) using Borosilicate glass having tip resistances of 0.5 to 1 MΩ.
Pulse Protocol and Solutions
These are described in the Data Supplement and illustrated in the representative figures.
Data Analysis
ECG Data
Mouse ECG waveforms over a 10-second period were averaged to obtain measurements of the RR, PR, QRS, QT, and QTc intervals and heart rate using LabChart (version8. 
Whole-Exome Sequencing
After informed consent, DNA was extracted from peripheral blood leukocytes and protein-coding regions targeted using the Agilent SureSelect All Exon V3 capture kit. High-throughput DNA sequencing was then performed using the Illumina HiSeq 2500 instrument with the paired-end sequencing protocol generating just under 100 million short (75 mb) sequence read pairs. 33 Raw sequence reads were aligned to the human reference (hg19) using the Burrows-Wheeler Aligner (0.6.9) aln algorithm after hard trimming to 50 bp. Duplicates were flagged using the Picard suite of tools. Postprocessing of the aligned data was done using the (GATK v1.6-19) including local realignment and base quality recalibration. Variant detection was done using the UnifiedGenotyper from GATK and called collectively to a multisample variant call format file. Low-quality sites were flagged using the VariantFiltrationWalker in agreement with the GATK BestPractices using filter thresholds Qual <50, QD <5, and AB >0.75.
mRNA Quantification
Real-time quantitative reverse transcription polymerase chain reaction was performed in HEK cells expressing SCN5A after 24-hour exposure to azithromycin or vehicle as described previously (Data Supplement).
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Protein Quantification
Western analysis to quantify SCN5A protein in HEK cells was performed as described (Data Supplement). [35] [36] [37] Both whole-cell lysate and biotinylated fraction were analyzed to quantify total cellular and plasma membrane-bound protein, respectively.
Azithromycin Plasma Concentrations
At 15 minutes after IP injection (when electrophysiological effects were maximal), animals were anesthetized with isofluorane, and blood was harvested by cardiac puncture. During oral administration, animals were euthanized at 90 minutes (the time to maximal plasma concentration; 31 n=4) or at 24 hours (at trough or predose; n=6) after the last dose for measurement of azithromycin plasma concentration. Plasma was isolated for extraction and analysis of azithromycin concentration using liquid chromatography-tandem mass spectrometry as described. 38 
Statistical Analysis
Data represented using a continuous variable were summarized using mean and SE for each group. For group comparisons of a repeated Figure 1 . Azithromycin-induced polymorphic ventricular tachycardia (VT) in a 24-y-old woman with no structural heart disease and a normal ECG. The arrhythmias resolved with stopping the drug. measure, the nonparametric Wilcoxon signed-rank test was applied. For independent group comparisons, the nonparametric Wilcoxon rank-sum test was used. Exact P values were calculated for these tests. For comparisons between multiple dose groups or time groups, P values were adjusted using the Bonferroni correction method. For each parameter of mouse ECG data, a linear regression with robust SEs and consideration of mouse cluster analysis were also performed. The mean differences between dose groups and the confidence intervals were estimated. Two-sided nominal level of 0.05 was considered as statistically significant. Analyses were performed using R 3.2.4 (https://www.R-project.org/), Origin Pro 2016 (Origin Laboratory Corporation, Northampton MA 01060), and Microsoft Excel 2010.
Results
Case Report
The patient was a 24-year-old black female with no medical history who was treated for 5 days with azithromycin (Zithromycin Z-Pak) for an upper respiratory infection. She was taking no other medications or supplements. Within 24 hours after discontinuing azithromycin, she experienced recurrent episodes of syncope and presented to a local emergency department. Her ECG on admission was normal ( Figure I in the Data Supplement). A rhythm strip obtained during a syncopal episode demonstrated rapid, polymorphic VT in the setting of a normal QT interval (Figure 1 ). She remained off azithromycin, and the VT resolved over 3 days. Cardiac magnetic resonance imaging was within normal limits. The patient received an implantable cardioverter-defibrillator before discharge. Whole-exome sequencing was performed, and there were no rare nonsynonymous variants identified in genes previously associated with inherited arrhythmia syndromes.
Acute Electrophysiological Effects of Azithromycin in Conscious Mice
As an initial step to investigate the electrophysiological effects of azithromycin in vivo, the drug was injected IP into conscious mice during continuous ECG monitoring. Within 15 minutes, azithromycin produced diffuse, dose-dependent depressant effects on cardiac automaticity and conduction ( Figure 2 ; Table 1 ), with reversible slowing of heart rate (Figure II in the Data Supplement), and significant increases in the PR, QRS, QT, and QTc intervals (Table I in the Data Supplement). Similar findings were observed after oral administration, with sinus slowing and an increase in all ECG intervals Table II in the Data Supplement) and to a lesser extent 24 hours after dosing. These results are consistent with the effects of azithromycin overdose in humans, and they imply that acute administration of azithromycin blocks multiple depolarizing and repolarizing ionic currents in cardiomyocytes.
In separate groups of mice, plasma azithromycin concentrations were determined after IP injection (at 15 minutes) and oral dosing (at 90 minutes when plasma concentrations were maximal, 31 and at 24 hours). Values were 0.09±0.03 and 0.26±0.4 μg/mL after 50 and 100 mg/kg IP injection, respectively (n=3 each). For oral administration, plasma concentrations were 0.12±0.01 and 0.07±0.01 μg/mL at 90 minutes and 24 hours post-dosing (n=4 and 6, respectively). For comparison, peak plasma concentrations in humans are shown during chronic oral dosing with the 3 azithromycin regimens available commercially (Table III in the Data Supplement, from the product package insert). Thus, azithromycin concentrations resembling those seen clinically were achieved during these experiments. However, the depressant ECG effects seen in the mouse are not observed clinically with oral administration in humans, demonstrating substantial interspecies pharmacokinetic differences.
Acute Effects of Azithromycin on Cardiomyocyte Action Potentials
To further confirm these effects for cardiomyocytes, we examined the effects of azithromycin on HL-1 cells, a cultured cardiac cell line that displays spontaneous automaticity. Acute exposure caused slowing of beat rate, a reduction in the phase 0 upstroke slope, and prolonged repolarization ( Table 2 
Reduction of SCN5A Currents With Acute Exposure
The QRS widening in vivo and reduced phase 0 upstroke in cardiomyocytes implied block of cardiac Na + current by azithromycin. In HEK cells expressing human SCN5A channels, azithromycin caused rapid block of I Na , with an IC 50 of ≈110 μmol/L, findings that were further confirmed in mouse ventricular myocytes (Figure 3A through 3D ; Table 3 ). Suppression of Na + current was accompanied by a depolarizing shift in the voltage dependence of channel activation and a hyperpolarizing shift in inactivation (Figure 3E and 3F; Table 3 ), changes that can account at least to some extent for the reduction in I Na observed.
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Paradoxical Time-Dependent Increase in Peak I Na
Recent studies have highlighted the importance of time-dependent effects of electrophysiologically active agents on cardiac I Na . 40, 41 To determine whether such properties might also be present for azithromycin, we characterized Na + current in cells chronically exposed to the drug (for 24 hours), compared with control (vehicle-exposed) cells. Interestingly, under these conditions, peak SCN5A current density was increased at all test potentials examined, with upregulation of ≈2-fold at −20 mV (Figure 4A and 4B; Table 4 ). As for acute exposure, the voltage dependence of channel gating was also modulated (Figure 4C and 4D; Table 4 ). However, in this case, these effects could not contribute to potentiation of cardiac I Na . These findings were replicated in HL-1 cardiomyocytes, with a substantial increase in Figure V in the Data Supplement). Consistent with this effect, the phase 0 upstroke slope was increased in HL-1 cardiomyocyte action potentials under similar conditions (Table 2 ; Figure IVD and IVE in the Data Supplement).
To explore the mechanism of azithromycin-mediated potentiation of Na + current, experiments were performed using real-time quantitative reverse transcription polymerase chain reaction and Western analysis to determine whether the drug altered the production of SCN5A mRNA, total cellular channel protein, or protein at the cell surface (using biotinylation). However, azithromycin had no effect on any of these properties for SCN5A ( Figure VI in the Data Supplement).
Time-Dependent Increase in Late I Na
Rarely, azithromycin causes drug-induced long-QT syndrome. One potential mechanism is an increase in the Na + window current, defined by overlap of the activation and inactivation curves, or a window of potentials over which a fraction of Na + channels are activated but not inactivated. However, µmol/L; n=5 for each concentration). E and F, Using the voltage-clamp protocols shown in the insets, normalized steady-state inactivation (E) and activation (F) curves for SCN5A were generated and fit with a Boltzmann function. AZ caused small but significant shifts in the hyperpolarizing and depolarizing directions, respectively (n=14-32; †P<0.01 for AZ 100 μmol/L in E and F). Proarrhythmic Effects of Azithromycin azithromycin caused either no change or a reduction, rather than an increase, in the window current with acute and chronic exposure ( Figure VII in the Data Supplement).
Because an increase in late Na + current can also prolong repolarization, we investigated the effects of azithromycin on this parameter using TTX subtraction in HEK cells expressing SCN5A ( Figure 5A ). Acute exposure to azithromycin had minimal effect on amplitude of late I Na ( Figure 5B ; Table 3 ); however, chronic exposure for 24 hours caused doubling of the late Na + current (Figure 5A and 5B; Table 4 ). Potentiation of late I Na was greater than the increase in peak I Na , illustrated by an increase in the ratio of these parameters ( Figure VIII in the Data Supplement). The effects of chronic azithromycin exposure to increase both peak and late I Na occurred at lower concentrations (IC 50 =40.9 and 62.2 μmol/L, respectively; Figure 5C and 5D) than those causing acute I Na block (IC 50 =110-116 μmol/L; Figure 3 ) implying greater clinical relevance during therapeutic dosing.
Minimal Effects on the Rapidly and Slowly Activating Delayed Rectifier K + Currents
Most drugs prolong cardiac repolarization by blocking the rapidly-activating delayed rectifier K + current, I Kr . In HEK cells expressing hERG, K + currents displayed only mild block by azithromycin, with an IC 50 of 219±21 μmol/L ( Figure 6 ; Table 5 ). Similarly, there was minimal effect of the drug on the slowly activating delayed rectifier, I Ks ( Figure 7 ; Table 5 ; IC 50 =184±12 μmol/L). Given that these concentrations are 3-to 4-fold higher than that for potentiation of late I Na , azithromycin-mediated QT prolongation most likely results from increased late Na + current, rather than K + channel block. Because azithromycin slows sinus node automaticity and prolongs atrioventricular nodal conduction in vivo, we tested the hypothesis that the drug blocks cardiac Ca ++ currents. Using rabbit ventricular myocytes, nimodipine-sensitive L-type Ca ++ currents were suppressed by azithromycin (IC 50 =67±4 μmol/L; Figure 8A and 8B; Table 5 ), while mibefradil-sensitive T-type Ca ++ currents were minimally affected (IC 50 not determined; Figure 8C and 8D; Table 5 ).
Azithromycin increased the maximal diastolic potential in HL-1 cells during both acute and chronic exposure (Table 2) , implying an effect on the inward rectifier current I K1 . Indeed, for HEK cells expressing Kir2.1 and for HL-1 cells, azithromycin suppressed Kir and I K1 currents, respectively (IC 50 =43.8 μmol/L for Kir2.1 currents; Table 5 ; Figure  IX in the Data Supplement).
Discussion
Azithromycin is a widely prescribed macrolide antibiotic that has been linked to an increased risk of sudden cardiac death and cardiovascular death. 11 In contrast to other macrolides, torsades de pointes has been rarely reported for azithromycin. [3] [4] [5] [7] [8] [9] Thus, the cause of these adverse events has remained poorly defined, prompting the present investigation. As demonstrated by the case presented here, azithromycin can cause a unique, drug-mediated proarrhythmic syndrome characterized by rapid, polymorphic VT in the absence of QT prolongation or demonstrable cardiac structural abnormalities. 6 We found that chronic drug exposure markedly potentiates cardiac Na ], providing a unifying mechanism for this unusual syndrome that likely contributes to azithromycin-mediated sudden cardiac death.
It is well recognized that conditions associated with intracellular Na + loading, most notably digoxin therapy and ischemia, alter intracellular Ca ++ homeostasis via the Na + -Ca ++ exchanger activity, with removal of Na + in exchange for Ca ++ , leading to delayed afterdepolarizations and triggered arrhythmias. 32 Abnormal intracellular Ca ++ homeostasis due to sarcoplasmic reticulum Ca ++ leak is the hallmark of catecholaminergic polymorphic VT, the clinical syndrome that most closely resembles this type of azithromycin proarrhythmia. Recent evidence further supporting the arrhythmogenic effects of cellular Na + loading derives from a transgenic mouse model in which peak Na + current was increased. 42 Mutations in Scn1b, encoding the Na + channel β 1 subunit, have been linked to inherited arrhythmia syndromes, including sudden infant death syndrome and unexplained death in epilepsy. 43, 44 Mice with cardiac-specific deletion of Scn1b demonstrated enhanced peak I Na , delayed afterdepolarizations, and polymorphic VT without APD prolongation, which was responsive to treatment with tetrodotoxin. Moreover, catecholaminergic polymorphic VT was recently linked to a gain-of-function mutation in Scn5a that increased Na + influx by augmenting the Na + channel window current. 45 Along with other studies, 46, 47 these data provide compelling evidence that a generalized increase in cardiac Na Azithromycin can cause life-threatening arrhythmias by at least 2 other mechanisms, although these seem to be rare. First, cases of drug-induced long-QT syndrome have been reported, but as noted above, documented torsades is unusual. Based on our results, potentiation of late I Na by azithromycin appears to be responsible for this adverse effect, occurring at much lower concentrations than those required for K + channel block. Drug-induced long-QT syndrome is less common with azithromycin than with other drugs that also increase late I Na , such as dofetilide. 41 This is likely because many of the compounds that increase late Na + current also block I Kr as well, and this is minimal with azithromycin. We speculate that concomitant block of cardiac Ca ++ current by azithromycin might also provide an additional potential protective mechanism to prevent early afterdepolarizations and torsades.
Second, acute intravenous exposure 14 (in one case causing overdose 15 ) can cause wide-spread depression of cardiac conduction, resulting in marked sinus bradycardia, slowing of AV nodal and infranodal conduction with heart block, and prolonged ventricular repolarization. For conscious mice and cardiomyocytes, we found that acute exposure to azithromycin had similar effects, with in vitro evidence of multi-ion channel block, providing a mechanistic basis for the electrophysiological effects of acute toxicity. Although these toxic effects have not been observed during oral dosing of azithromycin, we cannot rule out the participation of multi-ion channel block to drug-mediated sudden cardiac death. This is particularly true for acute Na + channel block, as well as block of I K1 , which would elevate the myocyte resting potential leading to both enhanced automaticity and additional Na + channel inactivation. An important consideration is the range of azithromycin concentrations that we studied. Several oral preparations of azithromycin have been marketed, and peak plasma concentrations during oral dosing range from ≈0.4 to 1.1 μmol/L (Table  III in the Data Supplement) . 48 However, plasma concentrations are misleading, as the drug accumulates within cells, achieving concentrations approaching 900 μmol/L in leukocytes and pulmonary tissue (Table III in •d −1 for 10 days), with ≈30-to 220-fold increase in concentration compared with plasma. 22 On the basis of these data and known azithromycin plasma concentrations in patients, we investigated azithromycin concentrations of 0.1 to 1000 μmol/L, to account for intracellular accumulation. Interestingly, amitriptyline also accumulates in 49 Intracellular concentrations were ≈5-fold higher than extracellular concentrations, explaining the drug's higher potency in cardiomyocytes compared with RYR2 channels incorporated into lipid bilayers.
The mechanism for azithromycin-mediated potentiation of cardiac Na + current remains unclear, as we found no evidence for increased production of SCN5A mRNA or total cellular protein, and there was no evidence for enhanced trafficking of channel protein to the cell surface. The alterations in channel gating, as well as the more selective increase in late I Na , also argue against a nonspecific or generalized effect to increase Na + channels at the membrane. We postulate that the increase in I Na is mediated by effects that alter post-translational modification and protein-protein interactions, which could be complex. 50 In conclusion, chronic exposure to azithromycin markedly potentiates cardiac Na + current to promote intracellular Na + loading, providing a unifying mechanistic basis for the distinct type of proarrhythmia seen with this drug. These findings imply that preclinical screening of new compounds should include examination of their pharmacological effects on cardiac I Na amplitude.
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